The present invention relates to method for producing hypo-metallated redox-active metallothionein (MT) proteins, pharmaceutical compositions containing the proteins, and uses the pharmaceutical compositions for treatment of conditions originating from elevated intracellular oxidative stress and/or dis-balanced intracellular redox-potential and/or redox-potential-dependent imbalance of metal ions.

A mitochondrion-targeting protein nanoparticle, containing related information such as an amino acid sequence thereof, a coding nucleic acid sequence, and a vector and a host expression bacterium for the coding nucleic acid. Under the induction of metal ions, the self-assembled protein nanoparticle mentioned above can be obtained by an Escherichia coli expression system. The protein nanoparticle can be applied in cancer diagnosis and treatment. Compared with existing mitochondrion-targeting small molecules (such as TPP and MPP), the protein nanoparticle can achieve properties of tumor enrichment, mitochondrion targeting, increasing of ROS content in cells, induction of cell apoptosis, inhibiting tumor growth, etc.

The present invention relates to a method of producing metal nanoparticles and metal sulfide nanoparticles using a recombinant microorganism co-expressing metallothionein and phytochelatin synthase, which are heavy metal-adsorbing proteins, and to the use of metal nanoparticles and metal sulfide nanoparticles synthesized by the method. The present invention provides a method for synthesizing metal nanoparticles which have been difficult to synthesize by conventional biological methods. The present invention makes it possible to synthesize metal nanoparticles in an environmentally friendly and cost-effective manner, and also makes it possible to synthesize metal sulfide nanoparticles. In addition, even metal nanoparticles which could have been produced by conventional chemical or biological methods are produced in a significantly increased yield by use of the method of the present invention.

The present invention relates to a method of producing metal nanoparticles and metal sulfide nanoparticles using a recombinant microorganism co-expressing metallothionein and phytochelatin synthase, which are heavy metal-adsorbing proteins, and to the use of metal nanoparticles and metal sulfide nanoparticles synthesized by the method. The present invention provides a method for synthesizing metal nanoparticles which have been difficult to synthesize by conventional biological methods. The present invention makes it possible to synthesize metal nanoparticles in an environmentally friendly and cost-effective manner, and also makes it possible to synthesize metal sulfide nanoparticles. In addition, even metal nanoparticles which could have been produced by conventional chemical or biological methods are produced in a significantly increased yield by use of the method of the present invention.

Metal-binding proteins, such as metallothionein proteins, are disclosed for removing metals from substrates in need of having such metals removed therefrom. Specifically, metallothionein proteins according to SEQ ID NO:1, 2, or 9-20 are disclosed for removing metals from liquid substrates. Associated methods for removing metals from substrates using metallothionein proteins are also disclosed.

Metal-binding proteins, such as metallothionein proteins, are disclosed for removing metals from substrates in need of having such metals removed therefrom. Specifically, metallothionein proteins according to SEQ ID NO:1, 2, or 9-20 are disclosed for removing metals from liquid substrates. Associated methods for removing metals from substrates using metallothionein proteins are also disclosed.

Metal bioremediation and metal mining strategies can include compositions and methods.

Metal bioremediation and metal mining strategies can include compositions and methods.

The present invention provides compositions and methods for the treatment or prevention of a lysosomal disease or disorder involving increasing the level, expression, or activity of a metallothionein polypeptide or polynucleotide in the subject.

The present invention provides compositions and methods for the treatment or prevention of a lysosomal disease or disorder involving increasing the level, expression, or activity of a metallothionein polypeptide or polynucleotide in the subject.